| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
3-Nitro-L-tyrosine is a biomarker of peroxynitrite formation and nitrosative stress rather than a conventional drug target. It serves as an indicator of oxidative damage mediated by reactive nitrogen species. The compound inhibits hemodynamic responses to angiotensin II, possibly through inhibition of alpha 1-adrenoceptor-mediated events. It is associated with inflammation and neurodegenerative diseases.
|
|---|---|
| ln Vitro |
In vitro, 3-Nitro-L-tyrosine is used to quantify the production of nitric oxide within cells. It serves as a measurable parameter for evaluating the level of nitric oxide production and oxidative stress. The compound's formation is studied by exposing tyrosine to peroxynitrite or other reactive nitrogen species. It is used in in vitro studies to map the spatial and temporal dynamics of nitrosative stress.
|
| ln Vivo |
In vivo, 3-Nitro-L-tyrosine is an indicator of systemic peroxynitrite exposure. It has been used to track peroxynitrite formation in various disease models. The compound induces motor neuron apoptosis. Its presence in tissues and biological fluids indicates nitrosative stress associated with inflammation, neurodegenerative diseases, and other pathological conditions.
|
| Enzyme Assay |
In vitro assays for 3-Nitro-L-tyrosine involve its detection and quantification as a biomarker of nitrosative stress. The compound is measured by HPLC, LC-MS, or ELISA in biological samples. For peroxynitrite studies, tyrosine is exposed to peroxynitrite and the formation of 3-nitrotyrosine is monitored. Antibody-based detection methods are used for immunohistochemical localization of protein-bound 3-nitrotyrosine. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
In vitro cell-based assays for 3-Nitro-L-tyrosine are conducted in various cell lines to study nitrosative stress. Cells are cultured in appropriate media and exposed to reactive nitrogen species or inflammatory stimuli. 3-Nitro-L-tyrosine levels in cell lysates or culture media are measured by ELISA or Western blot. Cell viability is assessed by standard assays. The compound is used as a marker to evaluate the extent of nitric oxide production and oxidative damage in cells.
|
| Animal Protocol |
In vivo animal studies for 3-Nitro-L-tyrosine are conducted to assess nitrosative stress in various disease models. Animals are treated with compounds that induce oxidative stress, and tissues are collected for 3-nitrotyrosine measurement by HPLC or immunohistochemistry. The compound's presence in tissues indicates peroxynitrite formation. For motor neuron apoptosis studies, animals are treated with 3-nitro-L-tyrosine and neuronal damage is assessed.
|
| ADME/Pharmacokinetics |
3-Nitro-L-tyrosine (MW 226.2 g/mol, C9H10N2O5) is soluble in DMSO at 2 mg/mL. It has a purity of ≥98%. The compound is light sensitive and should be stored under appropriate conditions. It is a stable marker of peroxynitrite activity and is used as an analytical standard in nitrosative stress research. Pharmacokinetic properties such as half-life and tissue distribution have been studied in rats.
|
| Toxicity/Toxicokinetics |
3-Nitro-L-tyrosine is a biomarker of nitrosative stress rather than a therapeutic agent. It induces motor neuron apoptosis. The compound is associated with oxidative damage and is found in elevated levels in various pathological conditions. It is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
3-Nitro-L-tyrosine is an L-tyrosine derivative with a nitro group attached to the 3-carbon atom of its benzene ring. It is an L-tyrosine derivative, belonging to the non-protein L-α-amino acid family, and is also a 3-nitrotyrosine. It is an enantiomer of 3-nitro-D-tyrosine. 3-Nitrotyrosine is a tyrosine derivative with a nitro group attached to the 3-carbon atom of its benzene ring. It is a product of tyrosine nitration, a reaction mediated by reactive nitrogen species, including peroxynitrite anions and nitrogen dioxide. 3-Nitrotyrosine is a biomarker of cellular damage, inflammation, and nitric oxide (NO) production; it is overproduced in many diseases where oxidative stress plays a key role.
3-Nitro-L-tyrosine (3-Nitrotyrosine) is a modified amino acid and the major product of peroxynitrite reaction with tyrosine. It serves as a stable footprint of peroxynitrite activity and a crucial biomarker for nitrosative stress. The compound inhibits hemodynamic responses to angiotensin II and induces motor neuron apoptosis. It is associated with inflammation and neurodegenerative diseases. Its molecular formula is C9H10N2O5 with a molecular weight of 226.2 g/mol.All applications are limited to non-human research use. |
| Molecular Formula |
C9H10N2O5
|
|---|---|
| Molecular Weight |
226.1861
|
| Exact Mass |
226.058
|
| CAS # |
621-44-3
|
| Related CAS # |
3-Nitro-L-tyrosine-d3;213386-10-8;3-Nitro-L-tyrosine-13C6
|
| PubChem CID |
65124
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
431.6±45.0 °C at 760 mmHg
|
| Melting Point |
233-235ºC (dec.)
|
| Flash Point |
214.8±28.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.651
|
| LogP |
0.6
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
278
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC(=C(C=C1C[C@@H](C(=O)O)N)[N+](=O)[O-])O
|
| InChi Key |
FBTSQILOGYXGMD-LURJTMIESA-N
|
| InChi Code |
InChI=1S/C9H10N2O5/c10-6(9(13)14)3-5-1-2-8(12)7(4-5)11(15)16/h1-2,4,6,12H,3,10H2,(H,13,14)/t6-/m0/s1
|
| Chemical Name |
(2S)-2-amino-3-(4-hydroxy-3-nitrophenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~5 mg/mL (~22.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4211 mL | 22.1053 mL | 44.2106 mL | |
| 5 mM | 0.8842 mL | 4.4211 mL | 8.8421 mL | |
| 10 mM | 0.4421 mL | 2.2105 mL | 4.4211 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
